W19-039 Assessment of transdermal penetration of gabapentin in cats.
(A Winn-funded grant project final progress report)
Principal Investigators: Jennifer Slovak; Nicolas Villarino; New York City Animal Medical Center
The investigators have completed their study enrolling a total of 23 cats in the pilot transdermal gabapentin study. Initially, eight of the client-owned cats were administered transdermal gabapentin in a Lipoderm® base at a dose of either 5mg/kg TID for 5 days or 10mg/kg TID for 5 days.
After the initial data was analyzed, an additional 15 cats were enrolled and were administered transdermal gabapentin on the ear at 10mg/kg TID. Blood collection occurred prior to gabapentin administration, 24 hours and 5 days post initiating gabapentin. All serum samples collected were trough samples, frozen at -80 and sent to the University of Tennessee’s Pharmacology Lab for analysis utilizing HPLC-mass spectroscopy.
The project is completed and the data prepared for a manuscript for publication.
Publications:
Abstract submission for the 2020 ACVIM Forum in June. Manuscript in current preparation.
Presentations:
An oral abstract is planned for the 2020 ACVIM Forum in June.
Summary prepared for Winn Feline Foundation © 2020